1. Home
  2. TRNO vs GKOS Comparison

TRNO vs GKOS Comparison

Compare TRNO & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Terreno Realty Corporation

TRNO

Terreno Realty Corporation

HOLD

Current Price

$65.87

Market Cap

7.0B

Sector

Finance

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$102.16

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRNO
GKOS
Founded
2009
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
6.0B
IPO Year
2009
2015

Fundamental Metrics

Financial Performance
Metric
TRNO
GKOS
Price
$65.87
$102.16
Analyst Decision
Buy
Strong Buy
Analyst Count
12
12
Target Price
$67.83
$126.92
AVG Volume (30 Days)
603.5K
1.0M
Earning Date
05-05-2026
04-29-2026
Dividend Yield
3.21%
N/A
EPS Growth
103.65
N/A
EPS
0.66
N/A
Revenue
$476,383,000.00
$507,442,000.00
Revenue This Year
$8.42
$23.32
Revenue Next Year
$9.10
$27.43
P/E Ratio
$100.91
N/A
Revenue Growth
24.51
32.33
52 Week Low
$53.00
$73.16
52 Week High
$67.55
$148.11

Technical Indicators

Market Signals
Indicator
TRNO
GKOS
Relative Strength Index (RSI) 50.88 28.38
Support Level $64.01 $92.38
Resistance Level $67.03 $102.80
Average True Range (ATR) 1.13 7.36
MACD -0.00 -4.94
Stochastic Oscillator 52.52 1.08

Price Performance

Historical Comparison
TRNO
GKOS

About TRNO Terreno Realty Corporation

Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: